Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3338017 | 0.79 | HPGD (0.34) | CHEK1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL16635249 | 0.77 | PDE10A (0.55) | PDE10ACHEK1MAP4K4PIK3CAKCNH2 | |
| SCHEMBL3340716 | 0.75 | KCNH2 (0.42) | MAP4K4PIK3CAKCNH2MINK1PI4KB | |
| SCHEMBL16635250 | 0.73 | PDE10A (0.43) | PDE10AMAP4K4PIK3CAKCNH2MINK1 | |
| SCHEMBL16635067 | 0.73 | NOTUM (0.46) | PDE10AMAP4K4PIK3CAKCNH2MINK1 | |
| SCHEMBL16635384 | 0.72 | PIK3CA (0.44) | PDE10AMAP4K4PIK3CAKCNH2MINK1 | |
| SCHEMBL30803710 | 0.72 | PDE10A (0.52) | PDE10ACHEK1MAP4K4PIK3CAKCNH2 | |
| SCHEMBL21284418 | 0.72 | PDE10A (0.52) | PDE10ACHEK1MAP4K4PIK3CAKCNH2 | |
| SCHEMBL16635658 | 0.71 | MAPT (0.43) | PDE10ATRPV3TRPA1 | |
| SCHEMBL21274241 | 0.71 | PDE10A (0.51) | PDE10ACHEK1MAP4K4PIK3CAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2025-09-11 | — | — | US | disclosed |
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20210284653-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2021-09-16 | — | — | US | disclosed |
| US-10941159-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200095259-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2020-03-26 | — | — | US | disclosed |
| US-10336769-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170320888-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2017-11-09 | — | — | US | disclosed |
| US-9422310-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150183800-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-8952161-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2155194-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20140024665-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2014-01-23 | — | — | US | disclosed |
| US-8481738-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120122891-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8084614-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2010-06-17 | — | — | US | disclosed |
| EP-2155194-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008124610-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320888-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | PDE10A 538/4885CHEK1 4581/4885MAP4K4 4369/4885 |
| US-20120122891-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | PDE10A 538/4885CHEK1 4581/4885MAP4K4 4369/4885 |
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | PDE10A 538/4885CHEK1 4581/4885MAP4K4 4369/4885 |
| US-20150183800-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | PDE10A 538/4885CHEK1 4581/4885MAP4K4 4369/4885 |
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | PDE10A 538/4885CHEK1 4581/4885MAP4K4 4369/4885 |
| US-20210284653-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | PDE10A 538/4885CHEK1 4581/4885MAP4K4 4369/4885 |
| US-10941159-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | PDE10A 538/4885CHEK1 4581/4885MAP4K4 4369/4885 |
| US-20140024665-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | PDE10A 538/4885CHEK1 4581/4885MAP4K4 4369/4885 |
| US-20200095259-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | PDE10A 538/4885CHEK1 4581/4885MAP4K4 4369/4885 |
| US-20100152207-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | PDE10A 533/4885CHEK1 4570/4885MAP4K4 4371/4885 |
| US-10336769-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | PDE10A 538/4885CHEK1 4581/4885MAP4K4 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.